Global Hemophilia Gene Therapy Market Size, Manufacturers, Opportunities and Forecast to 2030
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
According to APO Research, The global Hemophilia Gene Therapy market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Gene Therapy.
The Hemophilia Gene Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemophilia Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2019-2024, 2025-2030). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Hemophilia Gene Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Chapter 12: Concluding Insights of the report
According to APO Research, The global Hemophilia Gene Therapy market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Gene Therapy.
The Hemophilia Gene Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemophilia Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Spark Therapeutics
- Ultragenyx
- Shire PLC
- Sangamo Therapeutics
- Bioverativ
- BioMarin
- uniQure
- Freeline Therapeutics
- Hemophilia A
- Hemophilia B
- Hemophilia A Gene Therapy
- Hemophilia B Gene Therapy
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2019-2024, 2025-2030). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Hemophilia Gene Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Chapter 12: Concluding Insights of the report
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Hemophilia Gene Therapy Market Size Overview by Region 2019 VS 2023 VS 2030
1.4 Global Hemophilia Gene Therapy Market Size by Region (2019-2030)
1.4.1 Global Hemophilia Gene Therapy Market Size by Region (2019-2024)
1.4.2 Global Hemophilia Gene Therapy Market Size by Region (2025-2030)
1.5 Key Regions Hemophilia Gene Therapy Market Size (2019-2030)
1.5.1 North America Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
1.5.2 Europe Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
1.5.3 Asia-Pacific Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
1.5.4 Latin America Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
1.5.5 Middle East & Africa Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
2 HEMOPHILIA GENE THERAPY MARKET BY TYPE
2.1 Type Introduction
2.1.1 Hemophilia A
2.1.2 Hemophilia B
2.2 Global Hemophilia Gene Therapy Market Size by Type
2.2.1 Global Hemophilia Gene Therapy Market Size Overview by Type (2019-2030)
2.2.2 Global Hemophilia Gene Therapy Historic Market Size Review by Type (2019-2024)
2.2.3 Global Hemophilia Gene Therapy Market Size Forecasted by Type (2025-2030)
2.3 Global Hemophilia Gene Therapy Market Size by Regions
2.3.1 North America Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
2.3.2 Europe Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
2.3.3 Asia-Pacific Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
2.3.4 Latin America Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
2.3.5 Middle East and Africa Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
3 HEMOPHILIA GENE THERAPY MARKET BY APPLICATION
3.1 Type Introduction
3.1.1 Hemophilia A Gene Therapy
3.1.2 Hemophilia B Gene Therapy
3.2 Global Hemophilia Gene Therapy Market Size by Application
3.2.1 Global Hemophilia Gene Therapy Market Size Overview by Application (2019-2030)
3.2.2 Global Hemophilia Gene Therapy Historic Market Size Review by Application (2019-2024)
3.2.3 Global Hemophilia Gene Therapy Market Size Forecasted by Application (2025-2030)
3.3 Global Hemophilia Gene Therapy Market Size by Regions
3.3.1 North America Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
3.3.2 Europe Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
3.3.3 Asia-Pacific Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
3.3.4 Latin America Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
3.3.5 Middle East and Africa Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
4 GLOBAL MARKET DYNAMICS
4.1 Hemophilia Gene Therapy Industry Trends
4.2 Hemophilia Gene Therapy Industry Drivers
4.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
4.4 Hemophilia Gene Therapy Industry Restraints
5 COMPETITIVE INSIGHTS BY COMPANY
5.1 Global Top Players by Hemophilia Gene Therapy Revenue (2019-2024)
5.2 Global Hemophilia Gene Therapy Industry Company Ranking, 2022 VS 2023 VS 2024
5.3 Global Hemophilia Gene Therapy Key Company Headquarters & Area Served
5.4 Global Hemophilia Gene Therapy Company, Product Type & Application
5.5 Global Hemophilia Gene Therapy Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Hemophilia Gene Therapy Market CR5 and HHI
5.6.2 Global Top 5 and 10 Hemophilia Gene Therapy Players Market Share by Revenue in 2023
5.6.3 2023 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier
6 COMPANY PROFILES
6.1 Spark Therapeutics
6.1.1 Spark Therapeutics Comapny Information
6.1.2 Spark Therapeutics Business Overview
6.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
6.1.5 Spark Therapeutics Recent Developments
6.2 Ultragenyx
6.2.1 Ultragenyx Comapny Information
6.2.2 Ultragenyx Business Overview
6.2.3 Ultragenyx Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
6.2.5 Ultragenyx Recent Developments
6.3 Shire PLC
6.3.1 Shire PLC Comapny Information
6.3.2 Shire PLC Business Overview
6.3.3 Shire PLC Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
6.3.5 Shire PLC Recent Developments
6.4 Sangamo Therapeutics
6.4.1 Sangamo Therapeutics Comapny Information
6.4.2 Sangamo Therapeutics Business Overview
6.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
6.4.5 Sangamo Therapeutics Recent Developments
6.5 Bioverativ
6.5.1 Bioverativ Comapny Information
6.5.2 Bioverativ Business Overview
6.5.3 Bioverativ Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
6.5.5 Bioverativ Recent Developments
6.6 BioMarin
6.6.1 BioMarin Comapny Information
6.6.2 BioMarin Business Overview
6.6.3 BioMarin Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
6.6.5 BioMarin Recent Developments
6.7 uniQure
6.7.1 uniQure Comapny Information
6.7.2 uniQure Business Overview
6.7.3 uniQure Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
6.7.5 uniQure Recent Developments
6.8 Freeline Therapeutics
6.8.1 Freeline Therapeutics Comapny Information
6.8.2 Freeline Therapeutics Business Overview
6.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
6.8.5 Freeline Therapeutics Recent Developments
7 NORTH AMERICA
7.1 North America Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2 North America Hemophilia Gene Therapy Market Size by Country (2019-2024)
7.3 North America Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
8 EUROPE
8.1 Europe Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2 Europe Hemophilia Gene Therapy Market Size by Country (2019-2024)
8.3 Europe Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2019-2024)
9.3 Asia-Pacific Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
10 LATIN AMERICA
10.1 Latin America Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2 Latin America Hemophilia Gene Therapy Market Size by Country (2019-2024)
10.3 Latin America Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2019-2024)
11.3 Middle East & Africa Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
12 CONCLUDING INSIGHTS
13 APPENDIX
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Hemophilia Gene Therapy Market Size Overview by Region 2019 VS 2023 VS 2030
1.4 Global Hemophilia Gene Therapy Market Size by Region (2019-2030)
1.4.1 Global Hemophilia Gene Therapy Market Size by Region (2019-2024)
1.4.2 Global Hemophilia Gene Therapy Market Size by Region (2025-2030)
1.5 Key Regions Hemophilia Gene Therapy Market Size (2019-2030)
1.5.1 North America Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
1.5.2 Europe Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
1.5.3 Asia-Pacific Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
1.5.4 Latin America Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
1.5.5 Middle East & Africa Hemophilia Gene Therapy Market Size Growth Rate (2019-2030)
2 HEMOPHILIA GENE THERAPY MARKET BY TYPE
2.1 Type Introduction
2.1.1 Hemophilia A
2.1.2 Hemophilia B
2.2 Global Hemophilia Gene Therapy Market Size by Type
2.2.1 Global Hemophilia Gene Therapy Market Size Overview by Type (2019-2030)
2.2.2 Global Hemophilia Gene Therapy Historic Market Size Review by Type (2019-2024)
2.2.3 Global Hemophilia Gene Therapy Market Size Forecasted by Type (2025-2030)
2.3 Global Hemophilia Gene Therapy Market Size by Regions
2.3.1 North America Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
2.3.2 Europe Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
2.3.3 Asia-Pacific Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
2.3.4 Latin America Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
2.3.5 Middle East and Africa Hemophilia Gene Therapy Market Size Breakdown by Type (2019-2024)
3 HEMOPHILIA GENE THERAPY MARKET BY APPLICATION
3.1 Type Introduction
3.1.1 Hemophilia A Gene Therapy
3.1.2 Hemophilia B Gene Therapy
3.2 Global Hemophilia Gene Therapy Market Size by Application
3.2.1 Global Hemophilia Gene Therapy Market Size Overview by Application (2019-2030)
3.2.2 Global Hemophilia Gene Therapy Historic Market Size Review by Application (2019-2024)
3.2.3 Global Hemophilia Gene Therapy Market Size Forecasted by Application (2025-2030)
3.3 Global Hemophilia Gene Therapy Market Size by Regions
3.3.1 North America Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
3.3.2 Europe Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
3.3.3 Asia-Pacific Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
3.3.4 Latin America Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
3.3.5 Middle East and Africa Hemophilia Gene Therapy Market Size Breakdown by Application (2019-2024)
4 GLOBAL MARKET DYNAMICS
4.1 Hemophilia Gene Therapy Industry Trends
4.2 Hemophilia Gene Therapy Industry Drivers
4.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
4.4 Hemophilia Gene Therapy Industry Restraints
5 COMPETITIVE INSIGHTS BY COMPANY
5.1 Global Top Players by Hemophilia Gene Therapy Revenue (2019-2024)
5.2 Global Hemophilia Gene Therapy Industry Company Ranking, 2022 VS 2023 VS 2024
5.3 Global Hemophilia Gene Therapy Key Company Headquarters & Area Served
5.4 Global Hemophilia Gene Therapy Company, Product Type & Application
5.5 Global Hemophilia Gene Therapy Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Hemophilia Gene Therapy Market CR5 and HHI
5.6.2 Global Top 5 and 10 Hemophilia Gene Therapy Players Market Share by Revenue in 2023
5.6.3 2023 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier
6 COMPANY PROFILES
6.1 Spark Therapeutics
6.1.1 Spark Therapeutics Comapny Information
6.1.2 Spark Therapeutics Business Overview
6.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
6.1.5 Spark Therapeutics Recent Developments
6.2 Ultragenyx
6.2.1 Ultragenyx Comapny Information
6.2.2 Ultragenyx Business Overview
6.2.3 Ultragenyx Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
6.2.5 Ultragenyx Recent Developments
6.3 Shire PLC
6.3.1 Shire PLC Comapny Information
6.3.2 Shire PLC Business Overview
6.3.3 Shire PLC Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
6.3.5 Shire PLC Recent Developments
6.4 Sangamo Therapeutics
6.4.1 Sangamo Therapeutics Comapny Information
6.4.2 Sangamo Therapeutics Business Overview
6.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
6.4.5 Sangamo Therapeutics Recent Developments
6.5 Bioverativ
6.5.1 Bioverativ Comapny Information
6.5.2 Bioverativ Business Overview
6.5.3 Bioverativ Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
6.5.5 Bioverativ Recent Developments
6.6 BioMarin
6.6.1 BioMarin Comapny Information
6.6.2 BioMarin Business Overview
6.6.3 BioMarin Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
6.6.5 BioMarin Recent Developments
6.7 uniQure
6.7.1 uniQure Comapny Information
6.7.2 uniQure Business Overview
6.7.3 uniQure Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
6.7.5 uniQure Recent Developments
6.8 Freeline Therapeutics
6.8.1 Freeline Therapeutics Comapny Information
6.8.2 Freeline Therapeutics Business Overview
6.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue, Global Share and Gross Margin (2019-2024)
6.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
6.8.5 Freeline Therapeutics Recent Developments
7 NORTH AMERICA
7.1 North America Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2 North America Hemophilia Gene Therapy Market Size by Country (2019-2024)
7.3 North America Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
8 EUROPE
8.1 Europe Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2 Europe Hemophilia Gene Therapy Market Size by Country (2019-2024)
8.3 Europe Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2019-2024)
9.3 Asia-Pacific Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
10 LATIN AMERICA
10.1 Latin America Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2 Latin America Hemophilia Gene Therapy Market Size by Country (2019-2024)
10.3 Latin America Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2019-2024)
11.3 Middle East & Africa Hemophilia Gene Therapy Market Size Forecast by Country (2025-2030)
12 CONCLUDING INSIGHTS
13 APPENDIX
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
